Zeon Corporation has announced its decision to acquire the microfluidics business of Ushio Inc, boosting its healthcare and life sciences push.
The signing of a business transfer agreement took place on December 22, 2025. The transfer is set to take effect on February 1, 2026.
Through the acquisition, Zeon plans to accelerate growth in healthcare and life sciences, one of the four key growth areas outlined in its STAGE30 medium-term management plan.
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology, which uses 172 nm vacuum ultraviolet light to manufacture clean microfluidic chips with no chemical leachables.
“These microfluidic chips contribute to the development of Organs on chip (OoC) products, which are attracting growing attention in the fields of drug discovery and diagnostics,” the company said.
Zeon’s Cyclo Olefin Polymers (COPs), ZEONEX and ZEONOR, already widely used in lab equipment for biochemical analysis, will complement Ushio’s technology. Zeon highlighted that its COPs offer “low autofluorescence, high light transmittance, low biomolecules adsorption, and low impurities.”
By combining COP precision molding expertise with Ushio’s microfluidics know-how, Zeon aims to “strengthen collaboration with partners in the development of new tools, devices, and treatments, and to create new business opportunities in the fields of drug discovery and diagnostics.”
In Phase 3 of STAGE30, Zeon targets raising the sales ratio of its four growth areas to 48% of total sales by fiscal 2028, restructuring its business portfolio to focus management resources on these sectors.
Zeon affirmed its long-term vision: “Zeon remains committed to advancing a sustainable Earth and a safe, comfortable life for people by contributing to a sustainable society and delivering technologies, products, and services that are indispensable.”
,_Thyrocare.jpg)
